在动物试验中治疗稀有肿瘤 百分之百的成功。 Intensity Therapeutics' drug shows 100% success in treating rare tumors in animal tests.

强化治疗药物INT230-6显示,在临床预科试验中,对一种罕见的、具有攻击性的肿瘤类型,即恶性外围神经细胞肿瘤,百分之百的完整反应率是100%。 Intensity Therapeutics' drug INT230-6 showed a 100% complete response rate in preclinical tests on a rare, aggressive tumor type called malignant peripheral nerve sheath tumors. 在约翰·霍普金斯的一项研究中,所有经过治疗的动物都有完全的肿瘤反应,而未经治疗的动物肿瘤继续增长。 In a Johns Hopkins study, all treated animals had complete tumor responses, while untreated animals' tumors continued to grow. 这标志着在治疗这类神经癌症方面迈出了重要一步,尽管计划开展进一步的研究。 This marks a significant step in treating this type of neurological cancer, though further research is planned.